Insider Trading History of Kutok Jeffery

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Kutok Jeffery since 2018. This trader's CIK number is 1697644. At the time of last reporting, Kutok Jeffery was the Chief Scientific Officer of Epizyme, Inc.. (stock ticker symbol EPZM). Also see all insider trading activities at Epizyme, Inc..

Note that in the past Kutok Jeffery also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Epizyme, Inc. (EPZM) by Kutok Jeffery

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2022 EPZM 0 $0 5,297 $5,967 380,000 $528,200
2021 EPZM 0 $0 2,029 $17,855 0 $0

Yearly summary of insider trading at Infinity Pharmaceuticals, Inc. (INFI) by Kutok Jeffery

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2018 INFI 0 $0 28,626 $57,380 0 $0


Insider trading activities at 2 companies by Kutok Jeffery:

1. Epizyme, Inc. (EPZM)

2. Infinity Pharmaceuticals, Inc. (INFI)

Table 1. Insider trading of Epizyme, Inc. (EPZM) by Kutok Jeffery

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2022-08-09 EPZM Option Ex 380,000 1.39 528,200
2022-04-11 EPZM Sale 2,741 .90 2,466
2022-02-02 EPZM Sale 2,556 1.37 3,501
2021-04-05 EPZM Sale 2,029 8.80 17,855

Table 2. Insider trading of Infinity Pharmaceuticals, Inc. (INFI) by Kutok Jeffery

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2018-08-16 INFI Sale 6,133 2.00 12,266
2018-08-15 INFI Sale 8,180 2.01 16,417
2018-06-22 INFI Sale 14,313 2.00 28,697

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kutok Jeffery (Chief Scientific Officer of Epizyme, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.